---
title: "Taysha Gene Therapies taps Catalent for TSHA-102 Rett syndrome commercial manufacturing support"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294689795.md"
description: "Taysha Gene Therapies has entered a commercial supply agreement with Catalent for the manufacturing of TSHA-102, its gene therapy candidate for Rett syndrome. If FDA approved, Catalent will serve as the primary commercial manufacturer at its Maryland facility, ensuring long-term production capacity for a potential US launch. This partnership extends their development collaboration since 2020, with current efforts focused on BLA-enabling process performance qualification to ensure commercialization readiness."
datetime: "2026-08-03T12:02:17.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294689795.md)
  - [en](https://longbridge.com/en/news/294689795.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294689795.md)
generator: "portal-rs"
---

# Taysha Gene Therapies taps Catalent for TSHA-102 Rett syndrome commercial manufacturing support

-   Taysha Gene Therapies signed a commercial supply agreement with Catalent for TSHA-102, its gene therapy in pivotal development for Rett syndrome. \* Catalent is set to become the primary commercial manufacturer if the FDA approves TSHA-102, securing long-term capacity for a potential US launch. \* Manufacturing would run at Catalent’s FDA-licensed gene therapy facility in Harmans, Maryland, extending a development partnership in place since 2020. \* Taysha noted BLA-enabling process performance qualification work is underway to support commercialization readiness. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Taysha Gene Therapies Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608030800PRIMZONEFULLFEED9801882) on August 03, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [TSHA.US](https://longbridge.com/en/quote/TSHA.US.md)

## Related News & Research

- [Taysha Gene Therapies posts corporate deck highlighting TSHA-102 gene therapy program for Rett syndrome](https://longbridge.com/en/news/293788160.md)
- [Taysha Gene Therapies posts REVEAL Part A Phase 1/2 TSHA-102 Rett syndrome trial presentation](https://longbridge.com/en/news/291157030.md)
- [Is Wall Street Bullish or Bearish on Biogen Stock?](https://longbridge.com/en/news/296491913.md)
- [Great Lakes Advisors LLC Takes Position in Biogen Inc. $BIIB](https://longbridge.com/en/news/296676602.md)
- [Plato Investment Management Ltd Invests $1.49 Million in Biogen Inc. $BIIB](https://longbridge.com/en/news/296206286.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**